Trial · NCT07325240
24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients
NCT07325240, Phase 4, Recruiting, Mayo Clinic
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. 24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients. Trials, record NCT07325240. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07325240
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- 24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients
- NCT number
- NCT07325240
- Status
- Recruiting
- Phases
- Phase 4
- Enrollment
- 30 participants, estimated
- Lead sponsor
- Mayo Clinic
- Conditions
- Open Angle Glaucoma, Ocular Hypertension
- Interventions
- Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution, Latanoprost 0.005% Ophthalmic Solution
- First posted
- 2026-01-08
- Last updated
- 2026-05-01
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in mean Intraocular Pressure (IOP) | Change in mean IOP after 2 weeks of treatment with Latanoprost compared to baseline | Change in mean IOP from baseline at each time point for Latanoprost |
| Primary | Change in mean IOP | Change in mean IOP after 2 weeks of treatment with Rocklatan compared to baseline | Change in mean IOP from baseline at each time point for Rocklatan |
| Primary | Change in mean IOP | Change in mean IOP from baseline after 2 weeks of treatment with latanoprost minus change in mean IOP from baseline after 2 weeks of treatment with Rocklatan | Change in mean IOP from Latanoprost at each time point for Rocklatan |
| Secondary | Change in mean nocturnal IOP | Mean nocturnal IOP will be calculated based on the time points during the sleeping hours (11 PM - 7 AM) after 2 weeks of treatment with Latanoprost compared to baseline | Change in mean nocturnal IOP (both absolute and % change) from baseline for Latanoprost |
| Secondary | Change in mean nocturnal IOP | Mean nocturnal IOP will be calculated based on the time points during the sleeping hours (11 PM - 7 AM) after 2 weeks of treatment with Rocklatan compared to baseline | Change in mean nocturnal IOP (both absolute and % change) from baseline for Rocklatan |
| Secondary | Change in mean diurnal IOP | Mean diurnal IOP will be calculated based on the time points during the sleeping hours (7 AM - 11 PM) after 2 weeks of treatment with Latanoprost compared to baseline | Change in mean diurnal IOP (both absolute and % change) from baseline for Latanoprost |
| Secondary | Change in mean diurnal IOP | Mean diurnal IOP will be calculated based on the time points during the sleeping hours (7 AM - 11 PM) after 2 weeks of treatment with Rocklatan compared to baseline | Change in mean diurnal IOP (both absolute and % change) from baseline for Rocklatan |
| Other | 24-hour IOP variability | During the time period of analysis, approximately 18 months | 24-hour IOP variability based on standard deviation and range of measurements from 12 time points over a 24-hour period, and circadian amplitude from cosinor analysis of the 24-hour curve |
| Other | Diurnal IOP variability | During the time period of analysis, approximately 18 months | Diurnal IOP variability based on standard deviation and range of measurements during the waking period |
| Other | Nocturnal IOP variability | During the time period of analysis, approximately 18 months | Nocturnal IOP variability based on standard deviation and range of measurements during the sleeping period |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers14
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07325240
GET https://conductscience.org/api/trials/v1/NCT07325240/registered